CompletedNCT05587998
A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
Medication studyAges 18–55United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- Overland ParkSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: August 31, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 45
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT05587998
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Fixed Sequence Study to Assess the Effect on Respiratory Drive of Multiple Doses of AZD4041 When Co-administered With a Single Dose of Morphine in Healthy Recreational Opioid Users
Get this study by email
Recruitment & locations
CompletedOverland Park
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including Morphine and AZD4041.
Who was this study for?
Listed age limits: 18 years to 55 years.
